Team Up To Cure Cancer™
Give Hope and Life
The Ranelli Cancer Innovation Scholar™ endowed fund supports the most promising and innovative cancer research at the world-renowned Massachusetts General Brigham Cancer Institute (MGBCI).
Our mission is to accelerate life-changing breakthroughs in cancer treatment by empowering visionary scientists and physicians to pursue bold, high-impact ideas—without constraint.
Team up with us to turn innovation: into hope, discovery into life, and possibility into a cure.
Ranelli Cancer Innovation Scholar™
Photo by Michelle Rose, via Massachusetts General Hospital (MGH)
"This is not a battle any one person can fight alone. It requires the combined strength of everyone, everywhere."
— John Ranelli
Team Up To Cure Cancer™
Why This Fund Matters
Traditional research funding often rewards caution. The Ranelli Scholar™ endowed fund fuels boldness: the kind of daring innovation that can redefine cancer treatment to give families more time, more options, more life, and more hope.
Your Donation Supports
Every dollar ignites discovery by supporting: multi-disciplinary teams bridging research and care, cutting-edge labs, and clinical trials delivering faster solutions. These next-generation innovations allow us to go for a cure.
Team Up With Us
Changing the future of cancer treatment requires the combined strength of patients, families, doctors, and each of us. Help ignite the next breakthrough, the next moment of hope, and the next chance at life.
Considering a gift?
Here’s what inspired John & Ashley
Ranelli Scholar™
Photo by Michelle Rose, via MGH
The Ranelli Scholar™ program seeks to attract top-tier medical and scientific talent to MGBCI, with the audacious goal to deliver consistent breakthroughs in cancer treatments and a cure.
A Ranelli Scholar™ honoree is a true innovator, leading their own pioneering research to advance the cancer treatments and therapies of tomorrow.
Meet the Inaugural Ranelli Scholar™ Honoree, Dr. Matthew Frigault
The first Ranelli Scholar™ honoree is already changing the future of cancer research and treatment.
Dr. Matthew Frigault, is the clinical director of the MGBCI Cellular Therapy Service, and an assistant professor of medicine at Harvard Medical School.
His pioneering work with CAR T-cell Therapy, in which a patient’s own cells are modified to attack cancerous cells, is producing remissions in cancers previously considered untreatable, giving hope to patients who had exhausted all other options.
“Going back to the first discussions I had with people about cell therapy, the tone was that we're going for a cure. Having that kind of starting philosophy is powerful.”
— Dr. Matthew Frigault, Ranelli Scholar™ Honoree
Team Up To Cure Cancer™
Photo by Michelle Rose, via MGH
Please join us.
Questions?
For more information:
Email John Ranelli
Massachusetts General Brigham Cancer Institute
MGBCI is rated Top 5 in Cancer Hospitals by US News
Photo by Tracie Van Auken, via MGH
Top photo by John Crawford, courtesy the National Cancer Institute